{{Drugbox
| IUPAC_name = N-(2-isopropyl-5-methylcyclohexyl)-1-(4-methylbenzyl)-1,4-dihydrothieno[3',2':4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide
| image = NESS-040C5_structure.png
| width = 260

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_CA = Schedule II
| legal_status = 
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 1445751-90-5 
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 

<!--Chemical data-->
| C=27 | H=33 | N=3 | O=1 | S=1 
| molecular_weight = 447.64 g/mol
| smiles = CC(C=C1)=CC=C1CN2C3=C(CC4=C3SC=C4)C(C(NC5CC(C)CCC5C(C)C)=O)=N2
}}

'''NESS-040C5''' is a potent [[cannabinoid]] [[agonist]] which was developed for the treatment of [[glaucoma]].<ref>[http://www.google.com/patents/US8106218 Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218]</ref> It has reasonable selectivity for the [[Cannabinoid receptor 2|CB<sub>2</sub>]] receptor subtype, having a CB<sub>2</sub> affinity of 0.4nM, and 25x selectivity over the related [[Cannabinoid receptor 1|CB<sub>1</sub>]] receptor.<ref>Hanus LO, Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. ''Current Medicinal Chemistry''. 2010;17(14):1341-59. {{PMID|20166928}}</ref>

==See also==
* [[AB-FUBINACA]]
* [[NESS-0327]]
* [[SR-144,528]]

==References==
{{reflist}}

{{Cannabinoids}}
{{cannabinoid-stub}}
[[Category:Cannabinoids]]